Shares of Esperion Therapeutics ESPR decreased after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share were down 72.12% over the past year to ($3.89), which missed the estimate of ($3.76).
Revenue of $9,638,000 up by 881.47% year over year, which missed the estimate of $12,520,000.
Looking Ahead
Esperion Therapeutics hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Feb 23, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/h9ugsf9y
Technicals
Company's 52-week high was at $70.43
52-week low: $23.90
Price action over last quarter: Up 15.70%
Company Profile
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm has Business of researching, developing and commercializing therapies for the treatment of patients with the elevated LDL-C operating segment.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
